Showing: 11 - 15 of 15 RESULTS
Analyst Estimate Briefing Psyched Wellness Psychedelics

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could mature into leaders within their respective fields, some as soon as this year.” To start off this note, Tania Gonsalves says that in the past year, 20+ psychedelic companies have gone public, and 14 existing companies have now pivoted to …

Analyst Estimate Briefing Mind Medicine MindMed Psychedelics

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology analyst, has a C$2 price target and a speculative buy rating. Gonsalves comments, “As a clinical-stage biotechnology company, quarterly financials are not a materially impactful event, apart from unexpected variations in forecast cash burn.” Operating …

Analyst Estimate Briefing Mind Medicine MindMed Psychedelics

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating its speculative buy rating after the company closed its C$28.8 million financing. The financing saw the issuing of 27.4 million units, with each unit consisting of one common share and one half warrant at C$1.05 …

Analyst Estimate Briefing Mind Medicine Psychedelics

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from the recent two-day virtual non-deal roadshow that was hosted by Canaccord Genuity, which included JR Rahn and Stephen Hurst, co-CEOs of MMED, and Dr. Miri Halperin Wernli, who heads up MindMed Discovery. Canaccord’s analyst Tania Gonsalves reiterated their 12-month price …

Analyst Estimate Briefing Mind Medicine MindMed Psychedelics

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and a C$1.75 price target. Canaccord’s analyst Tania Gonsalves commented on the initiation, stating, “open your mind to a new kind of medicine” and that Mind Medicine “differentiated itself as one of the few legitimate companies in the space. Lead drug …